Press Releases

BASF Pharma Solutions and the Life Science business of Merck KGaA, Darmstadt, Germany announce the launch of a new standard for the electronic transfer of quality and regulatory documentation from suppliers to users in the pharma/biopharmaceutical industry. The Standard Quality and Regulatory Documentation (StaQRD) electronic data standard includes quality and regulatory compliance data. A previous eData standard, ASTM-E3077, published by the American Society for Testing and Materia

Latest data from GELITA, one of the leading international manufacturers of collagen peptides and tailored gelatins, indicate that it is on track to achieve its long term carbon neutrality targets. In its eighth Sustainability Report released this week [6 June], the company documented the progress it made between 2020 and 2022 against its sustainability commitments, covering the three dimensions of an ESG (Environment, Social and Governance) framework for the first time. A 50% reduct

Agilent Technologies Inc.today announced two new liquid chromatography mass spectrometry systems, the Agilent 6495D LC/TQ and the Agilent Revident LC/Q-TOF. Facilitating the high-end performance of the Revident LC/Q-TOF, Agilent is also announcing the new Agilent MassHunter Explorer Profiling software and the new Agilent ChemVista library manager software. The superior Agilent 6495 Triple Quadrupole LC/MS (LC/TQ) System is ideal for demanding and challenging targeted analysis applic

Transgene a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation , a leader in IT, network and AI technologies, announced that new data have been presented on TG4050, an individualized neoantigen cancer vaccine, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. TG4050 is based on Transgene's myvac platform and powered by NEC's cutting-edge AI capabilities. The new positive data

PharmaEssentia Corporation, a leading fully integrated biopharmaceutical company in Taiwan, today announced that it has entered into an exclusive license agreement with Pint-Pharma GmbH for the registration and promotion of BESREMi® (ropeginterferon alfa-2b-njft) for the treatment of polycythemia vera (PV), a rare blood cancer, in Brazil, Argentina, Colombia, Chile, Peru, Ecuador, and Mexico. “Expanding our geographic reach is critical to our mission to address clear gaps

The 9th edition of PharmaLytica, a premier pharmaceutical exhibition, commenced with an unwavering commitment to adapt to the changing healthcare landscape, and meet dynamic patient and business requirements. Organised by Informa Markets in India, the three- day event is taking place at HITEX, Hyderabad, hosting over 150 exhibitors. Allied to South Asia’s largest Pharma event, the CPhI & P-MEC India show, PharmaLytica is expected to witness over 6000 domestic and international visit

invoX Pharma Limited, a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited with an advancing pipeline of innovative products, today announced that it has completed a second tranche of investment in pHion Therapeutics (“pHion”), a next-generation mRNA vaccine company. The transaction supports invoX’s strategy to be a fully integrated biopharmaceutical company and its ongoing commitment to deliver innovative life-saving therapies pHion is developing

REALM IDx announced today the launch of REALM Pharma Services, an end-to-end discovery, translational research, and clinical trial service for biotechnology and pharmaceutical partners. Through a strategic integration, REALM Pharma Services brings together the research arms of subsidiaries, Ambry Genetics and Invicro, to offer cutting-edge genomics, traditional and molecular pathology, and advanced imaging and spatial biology. Combined with machine learning and artificial intelligence (AI) fr

Rocket Pharmaceuticals, Inc. a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to RP-A501, the Company’s investigational adeno-associated virus (AAV)-based gene therapy for the treatment of Danon Disease, a devastating and fatal inherited cardiomyopathy for which there are no cu

Pathalys Pharma, Inc., a private, late-stage biopharma company co-founded by Catalys Pacific and DaVita Venture Group, and Launch Therapeutics  a clinical development company, today announced that the first patient has been enrolled in the PATH (PTH Attenuation Trial in Hemodialysis) clinical program, consisting of two identical phase 3 trials, to assess upacicalcet for the treatment of secondary hyperparathyroidism (SHPT) in end-stage kidney disease (ESKD) patients on hemodialysis